

GP. 1642

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s): Dunstan

Serial No.: 09/389,545

Group Art Unit No.: 1642

Filed: September 3, 1999

Examiner: Helms, L

For: Compositions and Methods for the Prevention or Treatment  
of Cancer and Bone Loss Associated with Cancer

Docket No.: A-605

RECEIVED  
JAN 28 2000

**INFORMATION DISCLOSURE STATEMENT**

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:


As a means of complying with the duty of disclosure, applicant submits a "List of References Cited by Applicant" on a modified PTO-1449 form and provide a copy of each of the listed references for consideration by the Examiner.

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

Applicant requests consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge any filing fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc.

Respectfully submitted,

  
Robert B. Winter  
Attorney/Agent for Applicant(s)  
Registration No.: 34,458  
Phone: (805) 447-2425  
Date: JANUARY 18, 2000

Please send all future correspondence to:  
U.S. Patent Operations/ RBW  
Dept. 430, M/S 27-4-A  
AMGEN INC.  
One Amgen Center Drive  
Thousand Oaks, California 91320-1789

RECEIVED  
JAN 20 2000


RECEIVED  
JAN 28 2000

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, DC 20231, on the date appearing below.

1-18-2000

Date



Signature



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s): Dunstan

Serial No.: 09/389,545

Group Art Unit No.: 1642

Filed: September 3, 1999

Examiner: Helms, L

For: Compositions and Methods for the Prevention or Treatment  
of Cancer and Bone Loss Associated with Cancer

Docket No.: A-605

**INFORMATION DISCLOSURE STATEMENT**

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

As a means of complying with the duty of disclosure, applicant submits a "List of References Cited by Applicant" on a modified PTO-1449 form and provide a copy of each of the listed references for consideration by the Examiner.

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

Applicant requests consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge any filing fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc.

Respectfully submitted,

Robert B. Winter  
Attorney/Agent for Applicant(s)  
Registration No.: 34,458  
Phone: (805) 447-2425  
Date: *JANUARY 18, 2000*

Please send all future correspondence to:  
U.S. Patent Operations/ RBW  
Dept. 430, M/S 27-4-A  
AMGEN INC.  
One Amgen Center Drive  
Thousand Oaks, California 91320-1789

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, DC 20231, on the date appearing below.

1-14-2000

Date

*Allen Sorenson*

Signature